Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05690932 · ClinicalTrials.gov registry record · Phase 1
A Formulation Bridging and Food Effect Study of PBI-200 in Healthy Volunteers
A Phase 1 study, sponsored by Pyramid Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT05690932 is a Phase 1 study that has completed, run by Pyramid Biosciences. The registered enrollment target is 33 participants.
The verdict
NCT05690932, a Phase 1 study, has completed, sponsored by Pyramid Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
This is a single-dose, two-part, crossover formulation bridging and food effect study to assess the effect of formulation and food on the absorption and bioavailability of PBI-200 in normal, healthy volunteers.
Interventions
- DRUG PBI-200 Tablet
- DRUG PBI-200 Capsule
- DRUG PBI-200 Suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2022-02-24 |
| Est. Completion | 2022-05-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05690932
The ClinicalTrials.gov registry entry for NCT05690932 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pyramid Biosciences, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which PBI-200 Tablet is the first listed.
NCT05690932 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05690932 about?
NCT05690932 is a clinical study titled "A Formulation Bridging and Food Effect Study of PBI-200 in Healthy Volunteers". This is a single-dose, two-part, crossover formulation bridging and food effect study to assess the effect of formulation and food on the absorption and bioavailability of PBI-200 in normal, healthy volunteers.
What is the current status of trial NCT05690932?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2022-02-24. Estimated completion is 2022-05-23.
What interventions are being tested in trial NCT05690932?
The interventions under investigation include: PBI-200 Tablet (DRUG), PBI-200 Capsule (DRUG), PBI-200 Suspension (DRUG).
Who is sponsoring clinical trial NCT05690932?
This trial is sponsored by Pyramid Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.